Efficacy and Safety of SPC1001 in Patients With Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 252 participants.

Also called NCT06826872

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 252 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06826872
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06826872. Randomized; double masking; primary purpose treatment. Start 2024-06-12 (actual); primary completion 2025-10-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of SPC1001 in Patients With Essential Hypertension
Condition
Hypertension, Essential
Condition
Cardiovascular Diseases
Condition
Cardiology
Intervention (Drug)
SPC 1001 Mid2
Intervention (Drug)
SPC 2002
Intervention (Drug)
SPC 2003
Intervention (Drug)
SPC 2004
Lead sponsor
Shin Poong Pharmaceutical Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06826872
Content hash
cc09b74a60709c5d827c37e6032d227619bbdd0c8ffc1e1bc8188da14d2b2972